Methotrexate is an efficient therapeutic alternative in children with thiopurine-resistant Crohn’s disease

References

• Shanahan F. Crohn’s disease. Lancet 2002;359:62–9.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014;8:1179–207.
   PubMed Web of Science ®Google Scholar
• Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol 2007;102:2804–12.
   PubMed Web of Science ®Google Scholar
• Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cezard JP, et al. Efficacy of methotrexate in pediatric Crohn’s disease: a French multicenter study. Inflamm Bowel Dis 2006;12:1053–7.
   PubMed Web of Science ®Google Scholar
• Boyle B, Mackner L, Ross C, Moses J, Kumar S, Crandall W. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2010;51:714–17.
   PubMed Web of Science ®Google Scholar
• Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. J Pediatr 1998;132:830–5.
   PubMed Web of Science ®Google Scholar
• Weiss B, Lerner A, Shapiro R, Broide E, Levine A, Fradkin A, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr 2009;48:526–30.
   PubMed Web of Science ®Google Scholar
• Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr 2007;44:427–30.
   PubMed Web of Science ®Google Scholar
• Sunseri W, Hyams JS, Lerer T, Mack DR, Griffiths AM, Otley AR, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn’s disease. Inflamm Bowel Dis 2014;20:1341–5.
   PubMed Web of Science ®Google Scholar
• Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis–the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1–7.
   PubMed Web of Science ®Google Scholar
• Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, De Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795–806.
   PubMed Web of Science ®Google Scholar
• Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314–21.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439–47.
   PubMed Web of Science ®Google Scholar
• Daperno M, D’haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505–12.
   PubMed Web of Science ®Google Scholar
• Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982–1018.
   PubMed Web of Science ®Google Scholar
• Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–22.
   PubMed Web of Science ®Google Scholar
• Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease. J Gastroenterol 2014;49:638–45.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Laharie D, Reffet A, Belleannee G, Chabrun E, Subtil C, Razaire S, et al. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 2011;33:714–21.
   PubMed Web of Science ®Google Scholar
• Manosa M, Naves JE, Leal C, Cabre E, Moreno V, Lorenzo-Zuniga V, et al. Does methotrexate induce mucosal healing in Crohn’s disease? Inflamm Bowel Dis 2010;16:377–8.
   PubMed Web of Science ®Google Scholar
• Boyle BM, Kappelman MD, Colletti RB, Baldassano RN, Milov DE, Crandall WV. Routine use of thiopurines in maintaining remission in pediatric Crohn’s disease. World J Gastroenterol 2014;20:9185–90.
   PubMed Web of Science ®Google Scholar
• Mcdonald JW, Wang Y, Tsoulis DJ, Macdonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev 2014;8:CD003459.
   PubMed Web of Science ®Google Scholar
• Patel V, Wang Y, Macdonald JK, Mcdonald JW, Chande N. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2014;8:CD006884.
   PubMed Web of Science ®Google Scholar
• Willot S, Noble A, Deslandres C. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis 2011;17:2521–6.
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:863–73.
   PubMed Web of Science ®Google Scholar
• Griffiths A, Crandall W, Colletti R, Ruemmele F, Faubion WA, Hyams J, et al. Steroid-free remission in adalimumab-treated paediatric patients with moderately to severely active Crohn’s disease in the IMAgINE 1 trial. J Crohns Colitis 2014;8:S12.
   Web of Science ®Google Scholar